Multiomic landscape of immune pathogenesis in Kimura’s disease

Wu, Xunyao; Wang, Anqi; Wang, Xiaoxi; Guo, Dan; Zhu, Weiguo; Yang, Jing; Zhou, Jiaxin; Zhang, Wen; Duan, Minghui; Fei, Yunyun

doi:10.1016/j.isci.2023.106559

Cited by 3 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early research has shown that the ERK pathway plays a central role in cell signaling, particularly in regulating cell proliferation, differentiation, and survival [ 34 – 36 ]. The involvement of the ERK pathway has been widely recognized in monocyte activation and regulation [ 37 , 38 ]. However, previous studies have not provided a detailed explanation of how Plac8 regulates the ERK pathway [ 22 , 23 , 39 ].…”

Section: Discussionmentioning

confidence: 99%

Plac8-ERK pathway modulation of monocyte function in sepsis

Zhang,

Fu,

Chen

et al. 2024

Cell Death Discov.

View full text Add to dashboard Cite

Sepsis, a life-threatening condition caused by infection, is characterized by the dysregulation of immune responses and activation of monocytes. Plac8, a protein, has been implicated in various inflammatory conditions. This study aimed to investigate the effect of Plac8 upregulation on monocyte proliferation and activation in sepsis patients. Peripheral blood samples were collected from healthy individuals and sepsis patients. Monocytes were stimulated with lipopolysaccharide (LPS) to create an in vitro sepsis model, while a murine sepsis model was established using cecal ligation and puncture (CLP). The levels of monocyte markers, proliferation index (PI), and pro-inflammatory cytokines were assessed using flow cytometry and qPCR, respectively. Plac8 and phosphorylated ERK protein levels were determined by western blot, and TNF-α, IL-6, and IL-10 levels were quantified using ELISA. The CCK-8 assay was used to evaluate PBMC proliferation and activation. The results showed that Plac8 was highly expressed in sepsis models, promoting the survival, proliferation, and activation of monocytes. Plac8 upregulation activated the ERK pathway, leading to increased phosphorylation of ERK protein and elevated levels of CD14, CD16, TNF-α, IL-6, Plac8, and IL-10. In sepsis mice, Plac8 overexpression similarly activated the ERK pathway and promoted the survival, proliferation, and activation of monocytes. In conclusion, the upregulation of Plac8 enhances the activation of the ERK pathway and promotes monocyte proliferation and activation in sepsis patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Plac8-ERK pathway modulation of monocyte function in sepsis

Zhang,

Fu,

Chen

et al. 2024

Cell Death Discov.

View full text Add to dashboard Cite

show abstract

Kimura’s disease treated with dupilumab: A case report and literature review

Luo,

Zhou,

Wang

et al. 2024

International Immunopharmacology

View full text Add to dashboard Cite

Kimura disease: comprehensive analysis of clinical features, comorbidities, and treatment approaches

Zhu,

Zhang,

Zhang

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Kimura disease (KD) is a rare, chronic, inflammatory disorder characterized by painless subcutaneous masses, lymphadenopathy, elevated eosinophil counts and increased serum immunoglobulin E (IgE) levels. Due to the heterogeneity and rarity, current diagnostic and treatment approaches for KD are often delayed and have limited efficacy. Methods The clinicopathological data of 51 KD patients between January 2014 and December 2023 were retrieved and stratified based on age and mass size, respectively. A case ofrecurrent KD who responded well to a low dose of mepolizumab was described. Results We found that pruritus occurred in 45.8% of patients, with higher rates in older patients (P=0.033). Edema was observed in 29.2%, with higher prevalence in younger patients (P=0.010). The mean maximum mass size was 3.1cm, varying by age group (P=0.005). The mean time to diagnosis was 36 months, increasing with mass size (P=0.024). Meanwhile, we reported that one of these 51 patients was successfully treated with mepolizumab at a dose of 100mg every 4 weeks. Conclusion We conclude that pruritus and edema are the two main clinical manifestation of KD, and the size of mass is related to the time of diagnosis. Biologic agents targeting the Th2 pathway show promise for KD treatment.

show abstract

Multiomic landscape of immune pathogenesis in Kimura’s disease

Cited by 3 publications

References 41 publications

Plac8-ERK pathway modulation of monocyte function in sepsis

Plac8-ERK pathway modulation of monocyte function in sepsis

Kimura’s disease treated with dupilumab: A case report and literature review

Kimura disease: comprehensive analysis of clinical features, comorbidities, and treatment approaches

Contact Info

Product

Resources

About